Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
251.48
-1.66 (-0.66%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
66 Biggest Movers From Yesterday
October 29, 2021
Gainers HCW Biologics Inc. (NASDAQ: HCWB) shares surged 62% to close at $4.73 on Thursday after the company announced that it has been cleared by the U.S. Food and Drug...
Via
Benzinga
Why Alnylam Pharmaceuticals Is Crashing Today
October 28, 2021
The company's earnings fell short of expectations and its CEO is leaving.
Via
The Motley Fool
Analyzing Alnylam Pharmaceuticals's Unusual Options Activity
August 10, 2021
On Tuesday, shares of Alnylam Pharmaceuticals (NASDAQ:ALNY
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
October 28, 2021
Gainers Kiromic BioPharma (NASDAQ:KRBP) stock moved upwards by 21.62% to $2.25 during Thursday's regular session. Trading volume for Kiromic BioPharma's stock is...
Via
Benzinga
Alnylam Stock Dives As Sales Growth Falters And CEO John Maraganore Plans Exit
October 28, 2021
Alnylam fell on a disappointing quarter and plans for CEO John Maraganore to exit.
Via
Investor's Business Daily
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
October 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...
Via
Benzinga
Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity
October 28, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Planned CEO Leadership Transition
October 28, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Conference Call Discussing Third Quarter 2021 Financial Results
October 14, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
October 27, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
3 Growth Stocks Near 52-Week Highs to Buy Anyway
October 14, 2021
These top performers have what it takes to keep providing outsized gains for patient investors.
Via
The Motley Fool
Alnylam Announces Launch of “Alnylam Challengers,” a Signature Community Impact Program to Improve Health Access to Underserved Communities
October 13, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
October 24, 2021
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...
Via
Benzinga
Exposures
Product Safety
Where Alnylam Pharmaceuticals Stands With Analysts
October 12, 2021
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:
Via
Benzinga
10 Health Care Stocks With Unusual Options Alerts In Today's Session
October 08, 2021
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option...
Via
Benzinga
Analyst Ratings For Alnylam Pharmaceuticals
October 04, 2021
Over the past 3 months, 7 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:
Via
Benzinga
Alnylam Continues Scientific Leadership in Advancement of RNAi Therapeutics at the 17th Annual Meeting of the Oligonucleotides Therapeutics Society
September 29, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentation at Chardan Virtual 5th Annual Genetic Medicines Conference
September 28, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Submits Marketing Authorization Application to the European Medicines Agency for Investigational Vutrisiran for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy
September 13, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Presents Additional 9-Month Data from HELIOS-A Phase 3 Study of Vutrisiran at the European ATTR (EU-ATTR) Amyloidosis Meeting
September 07, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
September 01, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
This Robot-Run Large Cap ETF Has Less Apple, Microsoft, Amazon, Facebook Compared To SPY And Is Bullish On These Manufacturing Stocks Instead
August 18, 2021
The Qraft AI-Enhanced US Large Cap ETF (NYSE:QRFT) has revea...
Via
Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
August 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
August 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
August 11, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,...
Via
Benzinga
Exposures
Product Safety
Stocks That Hit 52-Week Highs On Tuesday
August 10, 2021
Before 10 a.m. ET on Tuesday, 100 stocks hit new 52-week highs. Things to Consider: The largest company by market cap to break to a new 52-week high was Pfizer (...
Via
Benzinga
Alnylam Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy
August 09, 2021
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Why Dicerna Pharmaceuticals Stock Is Tumbling on Friday
August 06, 2021
A less than satisfying result from a phase 2 trial with nedosiran makes the company's future difficult to predict.
Via
The Motley Fool
Why Is Dicerna Stock Getting Slammed Today?
August 06, 2021
Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) announced top-line results from PHYOX2 pivotal trial of nedosiran, RNAi therapeutic, for primary hyperoxaluria (PH). The...
Via
Benzinga
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
August 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)...
Via
Benzinga
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.